PSP Research LLC Acquires Shares of 12,655 Kiniksa Pharmaceuticals International, plc $KNSA

PSP Research LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) in the 4th quarter, Holdings Channel.com reports. The fund acquired 12,655 shares of the company’s stock, valued at approximately $522,000.

Several other hedge funds and other institutional investors have also made changes to their positions in KNSA. EverSource Wealth Advisors LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. Osaic Holdings Inc. bought a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $31,000. Quantbot Technologies LP bought a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at about $43,000. Quarry LP bought a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at about $44,000. Finally, TD Waterhouse Canada Inc. lifted its holdings in shares of Kiniksa Pharmaceuticals International by 1,673.9% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 2,040 shares of the company’s stock valued at $79,000 after acquiring an additional 1,925 shares during the last quarter. Institutional investors own 53.95% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Citigroup increased their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Wedbush increased their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a report on Wednesday, April 29th. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, May 6th. Canaccord Genuity Group increased their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Monday, May 4th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $60.86.

Kiniksa Pharmaceuticals International Price Performance

Kiniksa Pharmaceuticals International stock opened at $53.34 on Wednesday. Kiniksa Pharmaceuticals International, plc has a 1-year low of $25.70 and a 1-year high of $59.87. The firm has a market capitalization of $4.10 billion, a P/E ratio of 59.27 and a beta of 0.17. The company’s 50-day moving average is $48.98 and its 200 day moving average is $44.61.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. During the same period in the prior year, the company posted $0.11 EPS. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. Research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CAO Michael R. Megna sold 6,625 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total transaction of $309,321.25. Following the transaction, the chief accounting officer directly owned 27,418 shares of the company’s stock, valued at approximately $1,280,146.42. This trade represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the transaction, the chief executive officer directly owned 48,565 shares in the company, valued at approximately $2,623,481.30. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 653,301 shares of company stock worth $34,046,073 over the last three months. 51.98% of the stock is currently owned by company insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.